Posted by AGORACOM-JC
at 4:03 PM on Wednesday, November 24th, 2021
Liquid Avatar is a global blockchain & personal identity solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign digital Identity (“SSI”) .. … while also providing businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com).
As the digital universe has continued to expand, there is an ever-increasing need to verify online identity.
The internet has evolved from dot-com read-only to Web 2.0 read and engage to Web3 … which I can best describe as entering the Matrix for some older viewers amongst us OR RP1 for our younger investors.
The technical term is the Metaverse. First coined in Neal Stephenson’s 1992 sci-fi novel, Snow Crash, as a concept that blends digital and physical existence.
Oasis’ client Aftermath Islands has received significant interest on the sales from its initial Phase 1 launch of Virtual Land and is now launching its initial Virtual Land sales for Phase 2 of its metaverse platform. Like the previous Phase 1 group of islands, some of which are already sold out.
Meta Hero Project
A new 3D Meta Hero Project Avatar platform that allows users to fully customize and personalize their avatar with their life-like body type and photo-realistic face, together with unique skills and powers from a range of classes, giving them the ability to integrate with digital identity and be part of new and emerging online games and metaverse activities, including Aftermath Islands.
Meta Heroes combine gameplay, interactive engagement, and socialization seamlessly through fully controllable, high-quality, personalized 3D avatars. Meta Hero Project will be one of the first photo-realistic, life-like, customizable, personalized, and interactive NFTs, fully rigged for animation and play and that will conform to game, emerging metaverse, and digital identity standards.
This is next-level stuff that you aren’t going to want to miss. Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 5:10 PM on Tuesday, November 23rd, 2021
FansUnite Entertainment $FANS $FUNFF is a global sports and entertainment company, focusing on technology for online gambling. Specifically, they have produced a one-of-a-kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform operates multiple B2C brands and B2B software for the online gambling industry. More than just talk FANS has:
300,000+ registered members
$CDN 350,000,000 in betting volume over the last 3 years
Gambling licenses in the highly coveted U.K. and Malta
A successful $25,000,000 raise earlier this year to arm the company for acquisitions.
Today they announced a $USD 58,000,000 acquisition that can best be described by CEO Scott Burton in this powerful quote:
“The acquisition of American Affiliate represents the most significant milestone for FansUnite to date,” said Scott Burton, CEO of FansUnite Entertainment. “This transformative transaction will provide us further access to the lucrative U.S. regulated sports betting and online gambling market while generating accretive, high-margin revenue, expanding our leadership team, and accelerating the growth of our company’s footprint in the global gambling market.”
Some of the highlights of this acquisition are as follows:
Revenue and EBITDA Growth: American Affiliate has produced trailing 12 months unaudited revenue and EBITDA of US$13.1 million and US$6.0 million respectively.
High-Value Customer Base: American Affiliate’s assets have generated over 150,000 new depositing customers for legal U.S. online betting operators.
Partnerships with Tier-One Sportsbooks: Partnerships with leading sportsbooks and casinos including BetMGM, DraftKings, FanDuel, PointsBet, Underdog Fantasy, WynnBet, and more.
Strong Alignment with Existing Management and Shareholders: Consideration shares to be issued at a 42% premium to market price with share restrictions over a three-year period
World-Class Executive Team: Tier-one executive and management team with a history of success and scale in the U.S. gaming market
Leading Intellectual Property Portfolio: Category-leading portfolio of proprietary technology.
Posted by AGORACOM-JC
at 8:48 AM on Thursday, November 18th, 2021
The internet has evolved from Web 1.0 (dot-com read only) back in the 90’s to Web 2.0 (read and write) over the last 15 years to the current emergence of Web3 … which I can best describe as entering the Matrix (for some older investors) OR Ready Player 1 for our younger investors.
The technical term is the Metaverse. It’s already a $30B market BUT we haven’t seen anything yet based on the following:
According to Strategy Analytics, the global metaverse market size is projected to increase ~ 1,000% to $280 billion by 2025 from $30.7 billion in 2021 SOURCE … but we think that’s a very conservative estimate
Bloomberg Intelligence believes the Metaverse can reach $800 billion by 2024.
South Korea’s biggest asset manager, Samsung Asset Management, recently launched a metaverse fund.
IS THE METAVERSE HERE
It was always coming but we just didn’t know when because we needed two things to happen – the evolution of technology and acceptance.
The technology is now here thanks to AR, VR, Blockchain and the rise of NFTs, which Liquid Avatar has been at the forefront of since Day 1.
Acceptance was always a bit more of a wildcard because it is a pretty big shift – but the Covid-19 pandemic was the catalyst that drove the internet to the next stage of its evolution – the ‘Metaverse’ where cyberspace becomes more of an interactive 3D space with commerce and networking alongside content, much like the worlds in popular games such as Fortnite and Roblox,
Roundhill Investments, a major ETF sponsor focused on thematic and sector-specific investing stated “We Believe More Virtual Platforms Will Emerge … New virtual platforms will emerge, and they will likely exceed today’s leaders”
ENTER LIQUID AVATAR METAVERSE ENTRY WITH AFTERMATH ISLANDS
Two weeks ago Liquid Avatar announced that it’s Sale of Virtual Land NFTs in Aftermath Islands Metaverse Went Live . Though we don’t have official numbers yet, we do know that all virtual land in “Musk Manor” and “Bitcoin Bay” sold out pretty fast, so it’s safe to say that Aftermath Islands is off to great success.
With that kind of success, it’s no wonder $LQID is planning to showcase its Metaverse chops at what might be the biggest Comic Con of the year as we come out of COVID – LA Comic Con – where they were named as the Digital Innovation Partner back on October 26. Subsequently $LQID announced announced Hosting a Metaverse Mainstage Panel at Los Angeles Comic Con, Featuring Aftermath Islands ..where it will also has over 1,500 square feet of prime floor space that will showcase NFT subsidiary Oasis Studios, Aftermath Islands, comic and graphics art partner Apex Comics Group … and as yet to be announced “surprises”.
This week $LQID added another great element to Aftermath Islands, the first ever age verified islands as follows:
These are powerful initiatives because the genesis of $LQID is biometrically verified digital identity … giving the Company a substantial advantage in the race towards building the Metaverse.
If you’re a small cap investor that wants exposure to The Metaverse, make sure to watch this great interview with CEO David Lucatch.
In this episode of the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined for the second time by Dr. Paul Thielking, MD. He is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind.
Chief Scientific Officer, Dr. Paul Thielking speaks with Amanda Siebert from The Dales Report on the potential of psychedelics for palliative care and the role of group therapy.
Chief Medical Officer, Dr. Reid Robison discusses Novamind being granted DEA licenses for psilocybin research and our new Psychedelic Palliative Care program with AGORACOM.
Dr. Reid Robison opened the PSYCH Investor Summit with a keynote address presenting Novamind’s positioning and the rise and rollout of psychedelic medicine.
We are pleased to announce we have been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.
“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”
Psilocybin has shown significant positive outcomes for people with major depressive disorder¹ and for reducing anxiety and depression in people with life-threatening cancer.² As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.
“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”
Time magazine writes how the burnout, trauma and stress caused by the COVID-19 pandemic is opening the door to accelerated psychedelic research. “It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care. The world is experiencing mass trauma from COVID-19.” It’s especially true with frontline workers. The stats are alarming. The need has never been more apparent. It’s why we launched our Frontline Ketamine-Assisted Psychotherapy treatment program earlier this year. We’re providing healthcare workers with critical mental healthcare. You can learn more about the program here.
Therapeutic Goods Administration (TGA) in Australia is currently evaluating a proposal to reschedule two prominent psychedelics into a less restrictive classification. Mind Medicine Australia submitted the proposal to the government and “has the support of world leading experts in psychedelic research.” Novamind Chief Medical Officer, Dr. Reid Robison, will be presenting at the Mind Medicine Australia summit in November. Get your tickets here.
Could psychedelics follow the same path of cannabis toward legalization and regulation for medical purposes? It’s a question Luis Millán asks for National Magazine. “Despite the legal uncertainty, business is hopeful. Some stock market speculators believe psychedelics will follow in the footsteps of the cannabis industry and become the next billion-dollar business.”
Posted by AGORACOM-JC
at 4:12 PM on Wednesday, October 13th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
Q3 Highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products
The 2 multi-year product listings commenced on October 1, 2021
The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario
The agreement above supports $30M annual revenue target From blood thinner product alone!
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss self-compassion, why it is so hard (but so important) to forgive, and how to detox from judgement.
Novamind’s Chief Medical Officer opened the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Check back next week for footage of his presentation.
We are pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.
Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.
“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”
Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.
Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.
“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”
We announced our participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.
Novamind’s CEO and Director, Yaron Conforti, will present our progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of our sixth clinic and the newly launched Psychedelic Palliative Care program.
Virtual LD Micro Main Event XIV Date: October 13, 2021 Time: 10:30 AM to 11:00 AM EST Register and watch live here: me21.mysequire.com
In a collaboration with DoubleBlind magazine, Shelby Hartman and Madison Margolin explore how professional and economic systems are changing as the psychedelic revolution continues to grow. It’s not just about growth, though, but also the way we work. “What psychedelics offer is an invitation to look at professional and economic systems more, well, psychedelically.”
Covering Rick Doblin’s talk at the 2021 Annual Psychiatric Times World CME Conference, Leah Kuntz writes about what other conditions MDMA could treat including “depression, alcohol dependence, obsessive compulsive disorder, and even demoralization in AIDS survivors.” We look forward to further research on MDMA and will work to create treatment protocols for an array of mental health conditions, similar to our work with ketamine.
“According to estimates by the World Health Organization, about 300 million people worldwide live with depression.” It’s a stat that illuminates why there is so much urgency to bring psychedelic-assisted therapies to the world. We want to make a difference, to improve the quality of life for people suffering from depression and other mental health conditions, regardless of the psychedelic being used to bring about that lasting change. From Chief Medical Officer, Dr. Reid Robison: “I’m always touched by stories of hope and healing that come from witnessing the psychedelic modalities in action.”
Posted by AGORACOM-JC
at 10:01 AM on Wednesday, October 6th, 2021
12 months ago investors couldn’t be blamed if they found it hard to grasp the genius and foresight of Liquid Avatar $LQID $LQAVF ….. the easiest way to describe the company was as a blockchain platform allowing people to manage & profit from their digital identity, which became a real need once global laws started being enacted to prevent the likes of Facebook from every abusing our private information again.
Moreover, the platform also provides both businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com).
It sounded great … and definitely sounded like something you could see starting to happen 3-4 years into the future … but then the signs started showing up that painted an accelerating picture that would put LQID at the forefront of digital identity.
1. In March of this year, Google validated the $LQID business model with this stunning announcement:
Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
“Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,
What is the potential outcome of this major shift by Google?
“Google’s decision could upend the ad industry, which has relied on these types of tracking tools”
With this news, the data privacy and monetization game is underway and LQID sitting in a great position within the industry and the dominant position within the small cap world.
BUT THAT’S NOT ALL
2. In May of this year, The Ontario government released its digital identity strategy outlining ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments.
Then came the news all Liquid Avatar investors were waiting for:
the introduction of a new government-issued digital ID that lets people prove who they are both online and in person.
These 2 announcements out of Google and the Ontario Government officially put both business and government in the digital identity and credentials game. There is no looking back.
ENTER LIQUID AVATAR – WORKING WITH ONTARIO GOVERNMENT
Enter $LQID whose Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem, including the Holder, Issuer and Verifier, using state-of-the-art blockchain and open standards technologies . More than just a good idea, $LQID issued a press release announcing the following:
“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation”
AND
“Liquid Avatar Technologies has been a part of the ongoing consultations around the province’s plan to introduce a digital identification credential by the end of 2021”
ENTER LIQUID AVATAR – OUT OF DEVELOPMENT AND INTO COMMERCIALIZATION WITH 8,000 CONVENIENCE STORES
This morning $LQID released major news on the commercialization side whose title speaks for itself:
According to CEO Lucatch, this announcement represents a major inflection point as it signals a shift from development to commercialization, with many more potential deals in discussion.
LQID IS THE LEADING SMALL CAP COMPANY IN MASSIVE PARADIGM SHIFT TOWARD DIGITAL IDENTITY, PRIVACY AND MONETIZATION
Make no mistake about it. This is a simply massive paradigm shift and $LQID isn’t going to tackle this on its own. The Company is a voting and steering committee member of the Trust over IP Foundation, founding and steering committee member of Cardea, a Linux Foundation Public Health project, member of the Good Health Pass collaborative, ID2020, DIACC, The Linux Foundation and a founding member of the Lumedic Exchange.
Suddenly it is getting easy to see the genius of Liquid Avatar.
Watch this great interview with CEO David Lucatch.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss fear, the difference between pain vs. suffering, and the value of struggle in life.
We are pleased to announce the opening of our sixth integrative psychiatry clinic. The clinic is in Murray, Utah (the “Murray Clinic”).
The Murray Clinic also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population. The Company anticipates 65,000 visits to its clinics this year.
“Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment,” explained Yaron Conforti, CEO and Director. “We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”
The Murray Clinic is the latest in Novamind’s ongoing clinic expansion, with two additional clinics slated to open in Utah by the end of 2021. The Salt Lake City location is scheduled to open in October, while the Park City location will open in November to accommodate the construction of the Company’s new flagship clinic design.
Learn more about Novamind’s clinical research division here.
The evidence continues to grow in support of psychedelic medicine. In a piece for the Independent, Jonathan Sabbagh writes about how psychedelics, and ketamine-assisted psychotherapy in particular, changed his life. “For the first time, I understood the truth. My burnout wasn’t an end in itself. It was a symptom of a previously undiagnosed severe case of post-traumatic stress disorder.”
Axios breaks down why psychedelics matter, where they stand and what to watch for in the future. “Scientific studies of psychedelic therapies may be entering a new, broader phase thanks to more interest and funding from federal governments.” We will continue to research psychedelics and other innovative therapies at Cedar Clinical Research. CCR’s research sites are co-located with Novamind’s Cedar Psychiatry clinics allowing for large client population recruitment and providing clients access to innovative research stage treatments. And just this last week, we announced the opening of a new research site and clinic.
Posted by AGORACOM-JC
at 8:53 AM on Thursday, September 30th, 2021
Earlier today Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) opened its sixth integrative psychiatry clinic. The “Murray Clinic” also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population.
The Company anticipates 65,000 visits to its clinics this year.
Yaron Conforti, CEO and Director, “Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment. We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”
Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.
We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).
PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies.
“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.”
Additional information on the ETF can be found here.
Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare
We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.
Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.
Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.
We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.
The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers.
“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”
A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”
Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good.
